The C-type lectin domain family 12, member A (CLEC12A) receptor has emerged as a leukaemia-associated and cancer stem cell marker in myeloid malignancies. However, a detailed delineation of its expression in normal haematopoiesis is lacking.
| INTRODUCTION
The transmembrane receptor C-type lectin domain family 12, member A (CLEC12A) is emerging as a marker of blasts and leukaemic stem cells (LSC) in acute myeloid leukaemia (AML) and by inference as a useful tool in both the diagnostic and follow-up settings. [1] [2] [3] [4] [5] In addition, we have recently shown the relevance of this marker in the context of myelodysplastic syndrome (MDS). 6 In the setting of malignant haematology, one of the most appealing features of CLEC12A
is its lack of expression on CD34 + CD38 À cells in normal bone mar-stem cells, 2 making it a potential treatment target. Recent ventures in this regard include the development of anti-CD3/anti-CLEC12A bispecific antibodies. [7] [8] [9] The upcoming roles of CLEC12A as a cancer stem cell marker and potential treatment target emphasize the need of knowing the details of its expression pattern on early stem and progenitor cells in healthy individuals.
Although the classical roadmap of haematopoiesis is constantly being revised, [10] [11] [12] it is nevertheless providing a powerful tool for understanding the production of mature circulating blood cells and continuously serves as a solid model for studying clonal evolution in the myeloid spectrum of haematological malignancies. [13] [14] [15] [16] In this study, we opted to employ the immunophenotypic definition of the haematopoietic stem cell (HSC) as being Lin-CD34 The gating strategy used for analysing the myeloid progenitor cells is depicted in Figure 1 . In short, the lineage negative singlets were defined (not shown) and displayed in a CD34 vs. CD38 plot. Herein, the CD34 + CD38 + cell subset was defined ( Figure 1A ) and the progeni- 
CD38
À subset is depicted in Figure S1 . The number of analysed events and the corresponding percentages of CLEC12A + cells are given in Table S1 . Table S2 . Flow cytometry data from the sorting experiments (Donor 10-13) were included in the overall analyses of CLEC12A expression on myeloid progenitors.
| Colony-forming cell assay
Up to 500 sorted cells from subsets representing CLEC12A data not shown). To study at what level in the early human haematopoiesis CLEC12A
| Statistical analyses
is expressed, we employed a seven-colour tube (Table 1 ) and applied a stringent negative gating strategy based on FMO controls (Figure 1, S1 ). Consistent with previous observations, 2 we did not detect CLEC12A expression on either the HSCs or the MPPs in the Lin-CD34 + CD38 À subset (Table S1 ). For the MLP subset, the number of events was very low, and thus, it cannot formally be ruled out that a fraction of these cells could express CLEC12A (Table S1 ). in GMPs (P < .0001) and MEPs (P < .0001). Also, the mean CLEC12A + fractions were significantly different between GMPs and MEPs (P < .0001) (Table S1, Figure 2A) . Notably, the CLEC12A + cells
were distributed across the whole CMP and GMP compartments and extended into the MEP compartment ( Figure 2B ). Taken together, while CLEC12A is a known marker of mature myeloid cells, 23, 24 these data reveal that detectable expression of CLEC12A emerges at the level of the CMP, and is abundantly expressed on GMPs and to a lesser extent on the classically defined MEP. Figure 3 ). Being the most immature of the three cell types, the CMPs gave rise to both myeloid, erythroid and CFU-GEMM colonies in both the CLEC12A + and CLEC12A À subsets. The total number of colonies was significantly higher in the seeded CLEC12A À CMPs (P = .02). Moreover, significantly fewer erythroid colonies were observed in the seeded CLEC12A + CMP subset (P = .002),
showing that CLEC12A positivity favours a non-erythroid lineage.
For both CLEC12A +/À GMPs, the clonogenic growth was almost exclusively of myeloid origin and no CFU-GEMMs were evident (Table 2) , which is in accordance with the original definition of this cell subset. 22 We found no difference neither in the overall clonogenic potential of the CLEC12A + and CLEC12A À GMPs (P = and for CD34-AML even more mature progenitors/precursors. 15, 28 In addition, in low-risk myelodysplastic syndrome (MDS), the cancer stem cells have been shown to reside in the HSC compartment, 13 although studies on high-risk MDS indicate the MDS-propagating cell to arise in the MPP or GMP compartment, much resembling AML. 29, 30 In this context, the likely usefulness of CLEC12A as a mar- expression by cluster analysis and proved to be mutually exclusive with GATA1. 37 In this study, the GATA1 + (and thereby F I G U R E 3 Colony-forming cell assays on CLEC12A +/À CMPs, GMPs and MEPs from 6 normal donors. Asterisk (*) denotes mean number of colonies from plates seeded in doublets.
CLEC12A À ) cells gave rise to mast cells and eosinophils, while the GATA1 À (CLEC12A + ) cells gave rise to monocytes and neutrophils -cells that are also known to express CLEC12A in humans. 23, 24, 37 Interestingly, by adding the surface markers CD71 and BAH-1 to the established sorting schemes of myeloid progenitors, a study by Notta and colleagues found the originally defined CMPs to be quite heterogeneous and to consist of unipotent myeloid and erythroid progenitors with very sparse megakaryocyte activity. 11 In line with this, our data indicate that adding CLEC12A as a deselection marker in the sorting scheme of MEPs could purify the early erythroid subset further.
In conclusion, we here show the differentiated expression of CLEC12A at the level of myeloid progenitors and provide evidence that the earliest CLEC12A + cell in the haematopoietic tree is the classically defined CMP. While this knowledge is readily translational in the setting of CLEC12A-targeted treatment, we also suggest that the marker is continuously explored in basic research studying the early myeloid differentiation.
